Literature DB >> 32880686

Adiponectin treatment improves insulin resistance in mice by regulating the expression of the mitochondrial-derived peptide MOTS-c and its response to exercise via APPL1-SIRT1-PGC-1α.

Qi Guo1, Bo Chang2, Qiong-Li Yu1, Si-Tong Xu2, Xue-Jie Yi3, Shi-Cheng Cao4.   

Abstract

AIMS/HYPOTHESIS: Adiponectin stimulates mitochondrial biogenesis through peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α), a major regulator of mitochondrial biogenesis. MOTS-c (mitochondrial open reading frame of the 12S rRNA) is a biologically active mitochondrial-derived peptide encoded by mitochondrial DNA. It influences the mechanisms of obesity and diabetes. We hypothesised that the adiponectin pathway may regulate the production and/or secretion of MOTS-c in skeletal muscle. We aimed to determine whether exercise and adiponectin affect MOTS-c to improve insulin resistance in mice.
METHODS: To investigate this hypothesis, we used wild-type C57BL/6 mice subjected to high-fat diet, an exercise regimen, and i.p. injection of recombinant mouse adiponectin (Acrp30) or MOTS-c, and adiponectin knockout (Adipoq-/-) mice (C57BL/6 background) subjected to i.p. injection of Acrp30. C2C12 myotubes were also treated with sirtuin 1 (SIRT1) inhibitor, PGC-1α inhibitor, SIRT1 activator, plasmid-expressed active APPL1 (adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper), pcDNA-SIRT1, or siRNA against APPL1, SIRT1 or PGC-1α.
RESULTS: In Adipoq-/- mice, MOTS-c levels in the plasma and skeletal muscle were downregulated. In C2C12 myotubes, adiponectin increased the mRNA expression of MOTS-c. APPL1 protein level following adiponectin treatment positively correlated with MOTS-c protein and mRNA levels in C2C12 myotubes. SIRT1 overexpression increased the adiponectin-induced mRNA and protein expression of MOTS-c, SIRT1 and PGC-1α. Pharmacologic and genetic inhibition of PGC-1α suppressed the increases in MOTS-c mRNA and protein levels induced by SIRT1 overexpression. In mice, plasma and skeletal muscle MOTS-c levels were significantly downregulated following high-fat-diet. Exercise and i.p. Acrp30 or MOTS-c increased MOTS-c levels and adiponectin mRNA and protein expression in the plasma and skeletal muscle. CONCLUSIONS/
INTERPRETATION: Our findings showed that the APPL1-SIRT1-PGC-1α pathway regulates the production and/or secretion of skeletal muscle MOTS-c by mediating adiponectin signalling. Our study provides an insight into the cellular and molecular pathways underlying the pathogenesis of diabetes and shows that MOTS-c is a potential novel therapeutic target in the treatment of diabetes. Graphical abstract.

Entities:  

Keywords:  Adiponectin; Diabetes; Exercise-mediated signalling; MOTS-c; Mitochondrial biogenesis; Skeletal muscle

Year:  2020        PMID: 32880686     DOI: 10.1007/s00125-020-05269-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  4 in total

Review 1.  Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c).

Authors:  Tae Kwan Yoon; Chan Hee Lee; Obin Kwon; Min-Seon Kim
Journal:  Diabetes Metab J       Date:  2022-05-25       Impact factor: 5.893

2.  The mitochondrial signaling peptide MOTS-c improves myocardial performance during exercise training in rats.

Authors:  Jinghan Yuan; Manda Wang; Yanrong Pan; Min Liang; Yu Fu; Yimei Duan; Mi Tang; Ismail Laher; Shunchang Li
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

3.  Supplementation of Dimethylglycine Sodium Salt in Sow Milk Reverses Skeletal Muscle Redox Status Imbalance and Mitochondrial Dysfunction of Intrauterine Growth Restriction Newborns.

Authors:  Kaiwen Bai; Luyi Jiang; Qiming Li; Jingfei Zhang; Lili Zhang; Tian Wang
Journal:  Antioxidants (Basel)       Date:  2022-08-10

Review 4.  PGC-1α activity and mitochondrial dysfunction in preterm infants.

Authors:  Atefeh Mohammadi; Randa Higazy; Estelle B Gauda
Journal:  Front Physiol       Date:  2022-09-26       Impact factor: 4.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.